SNC
FRTX

Stifel Nicolaus & Co’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Stifel Nicolaus & Co’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-6
Closed -$61.3K – 1544
2013
Q2 		$61.3K Buy
+6
New +$66.5K ﹤0.01% 1358

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Litespeed Management New York $48.2M AUM 9.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Stifel Nicolaus & Co's FRTX Position: Q3 2013 in Review

Stifel Nicolaus & Co sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2013, closing a stake of 6 shares — an estimated $61.3K sold.

Stifel Nicolaus & Co first reported a position in FRTX in Q2 2013 and held it in 1 quarter. The position peaked at $61.3K in Q2 2013. 83 funds tracked by Wall St. Rank hold FRTX as of Q3 2013.

  • Stifel Nicolaus & Co reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • Stifel Nicolaus & Co sold 6 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2013, an estimated $61.3K.
  • Stifel Nicolaus & Co first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • Stifel Nicolaus & Co's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $61.3K in Q2 2013.
  • 83 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2013.

Based on Stifel Nicolaus & Co's 13F filing for Q3 2013, filed 13 Nov 2013.